Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Filiz Mercan Saridas"'
Publikováno v:
Heliyon, Vol 10, Iss 5, Pp e26900- (2024)
Background: Alemtuzumab (ATZ) is an anti-CD52 humanized monoclonal antibody indicated for treating highly active relapsing-remitting MS (RRMS). It alters the regulation of the immune system by depleting circulating lymphocytes. Changes in blood cell
Externí odkaz:
https://doaj.org/article/c8a56f5e62834646874dc30ab92aedc0
Autor:
Muge Yasar, Ensar Aydemir, Coskun Ates, Filiz Mercan Saridas, Erhan Hocaoglu, Mehmed Said Aydın, Soner Cander, Ozen Oz Gul, Erdinc Erturk, Canan Ersoy
Publikováno v:
Endocrine Abstracts.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::75db95c363eecbf00b036d89e3199117
https://doi.org/10.1530/endoabs.90.ep492
https://doi.org/10.1530/endoabs.90.ep492
Autor:
Ensar Aydemir, Coskun Ates, Yasemin Aydoğan Unsal, Erhan Hocaoglu, Filiz Mercan Saridas, Soner Cander, Ozen Oz Gul, Canan Ersoy, Erdinc Erturk
Publikováno v:
Endocrine Abstracts.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b627280042622eeed563623b9a2e32ce
https://doi.org/10.1530/endoabs.81.ep175
https://doi.org/10.1530/endoabs.81.ep175
Autor:
Coskun Ates, Erhan Hocaoglu, Ensar Aydemir, Filiz Mercan Saridas, Ozen Oz Gul, Soner Cander, Canan Ersoy, Erdinc Erturk
Publikováno v:
Endocrine Abstracts.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::edf2f978be694337decd7f88f600ebf6
https://doi.org/10.1530/endoabs.81.ep26
https://doi.org/10.1530/endoabs.81.ep26